Figure 4 | Scientific Reports

Figure 4

From: Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy

Figure 4

Mfn1 silencing improves the response to chemotherapy with a DNA damaging agent in a mice model of melanoma. shScr or shMfn1 B16-F1 cells were injected subcutaneously in the right hind leg of the mice, and when tumors became palpable mice were treated with three doses of DTIC (arrows). (a) Tumor size was measured at different time points p.t.i.. Two-way ANOVA with Tukey post-hoc analysis with respect to control (shScr) * P ≤ 0.01. Results are the mean ± SEM (n = 10). (b) Day 12 p.t.i., tumor volume before DTIC treatment. Unpaired t-test, two tails ***P < 0.0001 (n = 23). (c) Day 25 p.t.i., tumor volume after treatment. Two-way ANOVA, main effects of treatment (P = 0.0005), shRNA (P = 0.3) and their interaction (P = 0.6). Tukey post-hoc for multiple comparisons, different letters are significantly different (P ≤ 0.02). (df) mRNA levels of senescence marker or SASP components in the tumor. Two-way ANOVA (main effects of treatment, shRNA and their interaction) and Tukey post-hoc for multiple comparisons, different letters are significantly different: (d) Cdkn1a (p21) in the tumors (P < 0.0001, P = 0.004, P = 0.03), Tukey post-hoc P ≤ 0.0008. (e) Ccl5 (P < 0.0001, P = 0.3, P = 0.2), Tukey post-hoc P ≤ 0.0036. (f) Lgals9 (P < 0.0001, P = 0.5, P = 0.5), Tukey post-hoc P ≤ 0.009. (bf) Results are the mean ± SD (n = 10).

Back to article page